Ülke: Avrupa Birliği
Dil: Bulgarca
Kaynak: EMA (European Medicines Agency)
Emapalumab
Swedish Orphan Biovitrum AB (publ)
L04AA39
emapalumab
Immune System Diseases
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
Отказана